Table 2.
Biomarkers of systemic inflammation at baseline and 1 year, by vitamin D randomization.
| Active vitamin D, n = 784 | Placebo vitamin D, n = 777 | Overall percent change active/placebo vitamin D (95% CI) | P unadjusted modela | P adjusted modelb | |
|---|---|---|---|---|---|
| Baseline ln (IL-6) pg/mL, geometric mean (95% CI) | 1.71 (1.65–1.78) | 1.68 (1.61–1.74) | |||
| Year 1 ln (IL-6) pg/mL, geometric mean (95% CI) | 1.80 (1.73–1.87) | 1.63 (1.57–1.69) | |||
| Percent change from baseline (95% CI) | 5.08% (0.46–9.91) | −2.88% (−7.16 to 1.60) | 8.19% (1.52–15.31) | 0.02 c | 0.02 |
| Baseline ln (TNFR2) pg/mL, geometric mean (95% CI) | 2546.5 (2508.6–2584.9) | 2525.4 (2482.7–2568.9) | |||
| Year 1 ln (TNFR2) pg/mL, geometric mean (95% CI) | 2604.7 (2565.2–2644.7) | 2567.9 (2523.9–2612.7) | |||
| Percent change from baseline (95% CI) | 2.32% (1.13–3.53) | 1.68% (0.49–2.89) | 0.63% (−1.03 to 2.31) | 0.46 | 0.57 |
| Baseline ln (hsCRP) mg/L, geometric mean (95% CI) | 1.48 (1.40–1.57) | 1.51 (1.43–1.60) | |||
| Year 1 ln (hsCRP) mg/L, geometric mean (95% CI) | 1.62 (1.53–1.71) | 1.54 (1.46–1.63) | |||
| Percent change from baseline (95% CI) | 9.46% (2.93–16.39) | 2.18% (−3.94 to 8.68) | 7.12% (−1.81 to 16.87) | 0.12 | 0.16 |
a
Linear models comparing natural logarithm of biomarker concentration in active vs placebo vitamin D groups.
b
Linear models comparing natural logarithm of biomarker concentration in active vs placebo vitamin D groups, adjusted for age, sex, race, and n-3 FA randomized treatment group.
c
Values in bold indicate statistical significance, P < 0.05.